{"prompt": "['significant disability or incapacity; and/or generally requiring therapeutic', 'intervention.', 'All AEs will be followed until resolution, until deemed stable by the Investigator, or until the', 'patient is deemed by the Investigator to be lost to follow-up.', \"For clinical study safety reporting purposes, the most recent version of the Investigator's\", 'Brochure (IB) will be used as the reference document to designate event expectedness. An AE', 'is considered unexpected if the AE is not listed in the current IB or is not listed in the IB at the', 'specificity or severity observed.', 'Withdrawal from the study because of an AE and any therapeutic measures that are taken shall', 'be at the discretion of the Investigator. If a patient withdraws from the study for any reason, any', 'ongoing AEs will be followed until resolution, until deemed stable by the Investigator, or until', 'the patient is deemed by the Investigator to be lost to follow-up.', '10.14.', 'Reporting of Serious Adverse Events', 'Serious AEs (SAE) which occur from the time the patient provides informed consent to the end', \"of the study, require immediate notification to VI's Compliance Department or its designated\", 'representative. All SAEs must be reported within 24 hours of discovery, by faxing or emailing', 'the report.', 'The written report should be submitted on the SAE form provided for this purpose. The report', \"must include the Investigator's opinion as to whether the event is study drug-related. If this\", 'relationship is determined to be possibly, probably, or definitely related to study drug, evidence', 'to support this assessment must also be provided.', 'Documentation regarding the adverse event should be made as to the nature, date of onset, end', 'date, severity, and relationship to the investigational product, action(s) taken, seriousness, and', 'outcome of any sign or symptom observed by the Investigator or reported by the patient upon', 'direct questioning.', 'Expected outcomes related to the procedure should not be recorded as adverse events.', '10.15.', 'Sponsor Responsibility for Expedited Safety Reports', 'Vascular Insights or designee will notify Investigators of all reportable SAEs. This notification', 'will be in the form of an expedited safety report. Upon receiving such notices, the Investigator', 'must review and retain the notice with other study-related documentation.', 'The Investigator and Institutional Review Board (IRB)/Ethics Committee (EC) will determine if', 'the informed consent form requires revision. The Investigator should also comply with the', 'IRB/EC procedures for reporting any other safety information.', 'Suspected serious adverse reactions and other significant safety issues reported from the', 'investigational product development program shall be reported to the relevant competent health', 'authorities in all concerned countries per local regulations (either as expedited safety reports', 'and/or in aggregate reports), by the Sponsor or its designated representative.', 'Page 44 of 101']['For use of central IRB for the study, the Sponsor or its designated representative is responsible', 'for submission (or ensuring the submission) of the expedited safety reports to the appropriate', 'IRB for the study.', 'For this blinded trial, treatment will be unblinded by the Sponsor as necessary to determine the', 'need for expedited reporting, in accordance with global requirements.', 'Page 45 of 101']['11.', 'PLANNED STATISTICAL METHODS FOR ASSESSMENT OF', 'EFFICACY AND SAFETY', '11.1.', 'General Considerations', 'Continuous variables will be summarized using descriptive statistics, specifically the mean,', 'median, standard deviation, minimum and maximum. Categorical variables will be summarized', 'using frequencies and percentages. All statistical tests will be performed at the 0.05', 'significance level (p -value VI 0.050) unless otherwise indicated.', 'For efficacy analyses, missing post-treatment data will be imputed using last observation carried', 'forward (LOCF). Missing safety data will not be imputed.', '11.2.', 'Analysis Populations', '11.2.1.', 'Safety Population', 'The safety population will include all patients who are treated with ClariVein RES. Patients will', 'be analyzed per the treatment they received.', '11.2.2.', 'Modified Intent-to-Treat (MITT) Population', 'The MITT population will include all randomized and treated patients in the safety population', 'who have baseline and at least one post-treatment assessment for the primary efficacy variable.', 'Patients will be analyzed per their randomized dose of STS.', '11.3.', 'Primary Efficacy Endpoint', 'Improvement in patient reported symptoms at Week 12 post-treatment as compared to Baseline', 'using the weekly average HASTI (Heaviness, Achiness, Swelling, Throbbing, Itching) symptom', 'score from the VEINES-QOL/Sym, an instrument of Varicose Vein Symptom Burden in', 'patients with Superficial Venous.', '11.3.1.', 'Secondary Efficacy Endpoint', 'Elimination of saphenous vein reflux at Week 12 post-treatment as demonstrated by duplex', 'ultrasound.', '11.4.', 'Tertiary Enppoints', 'Assessment of patient improvement as compared to the Baseline assessment using the following', 'scales at post treatment Week 12 on the following Quality of Life or patient improvement', 'assessment:', 'Clinical-Etiology-Anatomy-Pathophysiology (CEAP) Classification', 'European Quality of Life scale (EQ-5D-5L)', 'Revised Venous Clinical Severity Score (rVCSS)', 'Wong Baker Visual Analog Pain Scale (VAS)', 'Page 46 of 101']\n\n###\n\n", "completion": "END"}